Discussing End-of-Life Care With a Patient

Article

Dr. Breitbart discusses how to have an effective end-of-life conversation with a patient.

William S. Breitbart, MD, acting chair at the department of psychiatry and behavioral sciences and chief of psychiatry service at Memorial Sloan-Kettering Cancer Center, discusses how to have an effective end-of-life conversation with a patient.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
A total of 30.0% and 31.5% of families with children undergoing chemotherapy for ALL experienced household material hardship or catastrophic income loss.

Catastrophic Income Loss Observed Among Families of Children with ALL

Alex Biese
December 6th 2025
Article

A total of 30.0% and 31.5% of families with children undergoing chemotherapy for ALL experienced household material hardship or catastrophic income loss.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

Survival Similar With MMUD Grafts in GVHD Care Regardless of Match Level

Roman Fabbricatore
December 6th 2025
Article

Among patients with an HLA-locus match level of less than 7, the rates of relapse and GVHD were similar to those with an HLA match level of 7.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

acute myeloid leukemia

MRD May Predict Survival in Induction Chemotherapy AML Trials

Russ Conroy
December 6th 2025
Article

Future work may expand analyses of measurable residual disease as a surrogate end point in AML to the use of modern, non-intensive treatment backbones.

The 2-year EFS end point was met in the cohort of patients given non-TBI conditioning and allogeneic HCT among those with B-ALL who are pre-HCT and NGS MRD-negative.

Efficacy Outcomes Remain Consistent Without Total Body Irradiation in B-ALL

Ariana Pelosci
December 6th 2025
Article

The 2-year EFS end point was met in the cohort of patients given non-TBI conditioning and allogeneic HCT among those with B-ALL who are pre-HCT and NGS MRD-negative.